HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Laurent Peyrin-Biroulet Selected Research

Inflammatory Bowel Diseases (Inflammatory Bowel Disease)

10/2015IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
8/2015Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience.
5/2015Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
5/2015Photodynamic therapy relieves colitis and prevents colitis-associated carcinogenesis in mice.
3/2015Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
1/2015Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
9/2014VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease.
7/2014Pharmacokinetics of adalimumab in inflammatory bowel diseases: a systematic review and meta-analysis.
3/2014Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT?
3/2014Association between 6-thioguanine nucleotides levels and clinical remission in inflammatory disease: a meta-analysis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Laurent Peyrin-Biroulet Research Topics

Disease

46Crohn Disease (Crohn's Disease)
12/2015 - 09/2006
38Inflammatory Bowel Diseases (Inflammatory Bowel Disease)
10/2015 - 01/2007
18Ulcerative Colitis
07/2015 - 04/2007
11Inflammation
05/2015 - 10/2006
9Necrosis
08/2015 - 07/2011
8Colitis
05/2015 - 04/2007
7Infection
08/2015 - 04/2007
7Fistula
08/2013 - 09/2006
6Neoplasms (Cancer)
05/2015 - 12/2006
3Pyoderma Gangrenosum
08/2015 - 01/2011
3Psoriasis (Pustulosis Palmaris et Plantaris)
08/2015 - 01/2011
3Uveitis
08/2015 - 01/2011
3Rheumatoid Arthritis
11/2013 - 07/2009
3Multiple Sclerosis
01/2011 - 09/2006
2Autoimmune Diseases (Autoimmune Disease)
01/2016 - 07/2009
2Erythema Nodosum
08/2015 - 01/2011
2Arthritis (Polyarthritis)
08/2015 - 01/2012
2Ankylosing Spondylitis
08/2015 - 01/2011
2Lymphoma (Lymphomas)
05/2015 - 10/2009
2Ileitis
11/2014 - 02/2008
2Opportunistic Infections (Opportunistic Infection)
08/2013 - 09/2006
2Abscess
08/2013 - 09/2012
2Colonic Neoplasms (Colon Cancer)
07/2013 - 11/2006
2Proctitis
06/2012 - 01/2008
2Hyperhomocysteinemia
02/2008 - 05/2007
1Keratoconus
12/2015
1Kidney Diseases (Kidney Disease)
12/2015
1Anemia
12/2015
1Immediate Hypersensitivity
10/2015
1Tetanus
08/2015
1Rubella (German Measles)
08/2015
1Poliomyelitis (Polio)
08/2015
1Smallpox (Variola)
08/2015
1Whooping Cough (Pertussis)
08/2015
1Measles
08/2015
1Mumps
08/2015
1Diphtheria
08/2015
1Aphthous Stomatitis (Aphthous Ulcer)
08/2015
1Periodontitis
05/2015
1Skin Ulcer
05/2015
1Encephalomyelitis (Myeloencephalitis)
05/2015
1Soft Tissue Infections
05/2015
1Wounds and Injuries (Trauma)
05/2015
1Experimental Arthritis
05/2015
1Ulcer
03/2015

Drug/Important Bio-Agent (IBA)

26infliximab (Remicade)FDA Link
10/2015 - 11/2006
15Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2015 - 06/2008
15adalimumab (Humira)FDA Link
06/2015 - 04/2007
8Azathioprine (Imuran)FDA LinkGeneric
05/2015 - 12/2008
7C-Reactive ProteinIBA
05/2015 - 12/2010
6Immunologic Factors (Immunomodulators)IBA
12/2015 - 02/2010
6Immunosuppressive Agents (Immunosuppressants)IBA
09/2014 - 07/2013
5Phenobarbital (Luminal)FDA Link
12/2015 - 06/2008
5AntibodiesIBA
10/2015 - 08/2013
5Vitamin B 12 (Cyanocobalamin)FDA LinkGeneric
05/2013 - 05/2007
5Folic Acid (Vitamin M)FDA LinkGeneric
11/2011 - 12/2006
4Primary sclerosing cholangitisIBA
08/2015 - 11/2006
4HomocysteineIBA
04/2008 - 05/2007
3Dihydrotachysterol (AT 10)IBA
08/2015 - 01/2012
3vedolizumabIBA
07/2015 - 02/2014
3golimumabFDA Link
05/2015 - 02/2014
3Mesalamine (Mesalazine)FDA LinkGeneric
03/2015 - 01/2013
3Leukocyte L1 Antigen Complex (Calgranulin)IBA
11/2014 - 09/2013
3CDP870FDA Link
12/2010 - 06/2008
3Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA
04/2008 - 05/2007
2tranilast (N 5')IBA
12/2015 - 07/2013
2VaccinesIBA
08/2015 - 04/2011
2natalizumab (Tysabri)FDA Link
07/2015 - 09/2006
26-Mercaptopurine (Mercaptopurine)FDA LinkGeneric
05/2015 - 08/2009
2Biological Markers (Surrogate Marker)IBA
11/2014 - 01/2014
2Thioguanine (Tioguanine)FDA Link
03/2014 - 12/2008
2NucleotidesIBA
03/2014 - 12/2008
2Methotrexate (Mexate)FDA LinkGeneric
03/2014 - 12/2010
2Monoclonal AntibodiesIBA
06/2013 - 01/2011
2SteroidsIBA
06/2013 - 06/2011
2galactoside 2-alpha-L-fucosyltransferase (Fucosyltransferase 2)IBA
05/2013 - 02/2012
2VitaminsIBA
02/2012 - 07/2009
2Messenger RNA (mRNA)IBA
01/2012 - 11/2011
2Superoxide DismutaseIBA
11/2011 - 02/2008
1Pediatric ulcerative colitisIBA
01/2016
1IronIBA
12/2015
1Immunoglobulin E (IgE)IBA
10/2015
1Rubella VaccineIBA
08/2015
1N-acetyltalosaminuronic acid (NAT)IBA
07/2015
1cyclo(Arg-Pro) (CI 4)IBA
05/2015
1chlorinIBA
05/2015
11-phenyl-3,3-dimethyltriazene (PDT)IBA
05/2015
1temoporfinIBA
05/2015
1monoclonal antibody CNTO 1275 (CNTO 1275)FDA Link
03/2015
1Carbon MonoxideIBA
11/2014
1Vascular Endothelial Growth Factor CIBA
09/2014

Therapy/Procedure

8Colectomy
07/2015 - 02/2008
3Biological Therapy
11/2014 - 04/2011
2Photochemotherapy (Photodynamic Therapy)
05/2015 - 05/2015
1Drug Therapy (Chemotherapy)
12/2015
1Refractive Surgical Procedures
12/2015
1Retreatment
10/2015
1Remission Induction
07/2015
1Palliative Care (Palliative Medicine)
09/2014
1Enteral Nutrition (Feeding, Tube)
09/2014